ABSTRACT
INTRODUCTION

Retinal ON bipolar cells (ON BCs
(1). Patients with CSNB1 present in early childhood with impaired night vision, and can be diagnosed by ERG, where they display a distinctive absence of the ON BC-driven b-wave, while maintaining a normal photoreceptor a-wave (2). CSNB1 patients also exhibit other phenotypes including severe myopia, strabismus and nystagmus (3). Mouse models harboring mutations in homologous CSNB1 genes such as Grm6 (4-7), the non-selective cation channel TRP melastatin 1 (Trpm1) (8-10), the orphan G protein receptor (Gpr179) (11) and two leucine rich repeat proteins, nyctalopin (Nyx) (12) (13) (14) and Lrit3 (15, 16) faithfully recapitulate the no b-wave ERG phenotype seen in CSNB1 patients and collectively will be referred to as 'nob' mice. These proteins are all localized to the dendritic tips of ON BCs and their mouse models have been used to interrogate the role of each in the mGluR6 cascade (Figure 1) . From these studies we know that in the absence of light, glutamate released from photoreceptors binds to the metabotropic glutamate receptor6 (mGluR6) (17, 18) and activates a G-protein, G o (19, 20) .
While the exact cascade sequence remains unknown, it is clear that the initial step requires dissociation of G-protein subunits and culminates in closure of the TRPM1 cation channel (21-23). NYX is required for the correct localization of TRPM1 (24), whereas GPR179 mediates channel sensitivity (25). LRIT3 interacts with both NYX and TRPM1 (24, 26, 27) . Despite the disruption in ON BC signaling, mutations in these cascade proteins have no effect on retinal morphology in CSNB1 patients or respective mouse models (1). This suggests they are good candidates for gene replacement therapy.
Adeno associated virus (AAV) has demonstrated remarkable success both in clinical trials for inherited retinal disease, as well as in a multitude of proof of concept experiments (28-34).
Retinal pigment epithelium and photoreceptors are efficiently targeted by various AAV serotypes following delivery to the subretinal space. Retinal ganglion cells are efficiently transduced following vitreal delivery (35, 36) . Transduction of inner nuclear layer cell types (e.g., ON BCs) within non-degenerate retinas and selective transgene expression in ON BCs has proven challenging. This is due to the inability of most AAV serotypes to efficiently traffic to cells of the inner retina. To date, AAV has been used only to deliver xenogenic microbial opsins, an artificial by guest on November 7, 2016 http://hmg.oxfordjournals.org/ Downloaded from iGluR6-based optical switch, or melanopsin-derived light sensors to ON BCs, all with the goal of conferring light sensitivity to second order neurons in mouse models lacking photoreceptors (37-41). In all instances, transgene expression was driven in ON BCs by a Grm6 enhancer sequence fused to the SV40 promoter. Because these studies were conducted in rodent models exhibiting advanced photoreceptor degeneration, it is unclear whether the Grm6/SV40 promoter would be suitable for driving selective expression in ON BCs in non-degenerate, stationary models such as nob mice.
To this end, we developed a novel AAV vector and cellular promoter combination capable of driving efficient and targeted transgene expression in ON BCs of non-degenerate mouse retina following intravitreal injection. We show that AAV2(quadY-F+T-V)-Ple155 mediates transgene expression in ON BCs, and restores ON BC signaling in C57BL/6J (WT) and in the Nyx nob mouse model of CSNB1. This is the first demonstration that an inherent genetic defect of ON BCs can be corrected with AAV-based gene therapy. Our results have implications for the development of gene therapies for NYX and other forms of CSNB1 and for non-invasive optogenetic manipulation of ON BC signaling.
RESULTS
AAV2(quadY-F+T-V)-Ple155 drives robust and targeted transgene expression in ON BCs
We previously identified an AAV2-based capsid variant capable of transducing the majority of retinal cells following intravitreal injection in mouse (36). We combined this variant with our recently described human MiniPromoter, "Ple155" that promotes transgene expression in BCs of single-copy knock-in mice (42) , and evaluated its ability to drive GFP expression in BCs of C57BL/6J (WT) and Nyx nob mice following either subretinal or intravitreal injection (Figure 2) . In adult WT mouse retina, AAV2(quadY-F+T-V)-Ple155-mediated GFP expression was targeted to BCs. Transduction by subretinal delivery was inefficient (Figure 2A ) compared to intravitreal injection in either WT or Nyx nob retina (Figure 2B and 2C) . AAV-mediated GFP expression colocalized with protein kinase C alpha (PKCα) (Figure 2A/C) , a marker of rod BCs, as well as purkinje cell protein 2 (PCP2) (Figure 2B ), a marker of rod and a subset of cone ON BCs and the source gene for the Ple155 MiniPromoter design (42) . GFP expression was observed in middle retina, with fluorescence localized to the somas and dendritic tips of ON BCs. GFP was also seen in the axon terminals of the ON BCs and was noted in some (albeit very few) retinal ganglion cells (RGCs) in the inner retina. Intravitreal injection results in RGCs being exposed to a high concentration of vector particles. Even photoreceptor targeted promoters such as GRK1 Figure 1) .
We compared the relative abilities of Ple155 and the previously described Grm6/SV40 enhancer/promoter combination to drive transgene expression exclusively in ON BCs in a nondegenerative retina. AAV8(Y733F)-Grm6/SV40-hChR2-eGFP delivered subretinally to WT mice promoted off-target GFP expression primarily in photoreceptors (Supplemental Figure 2) (37).
For its increased specificity relative to Grm6/SV40 in non-degenerate retina, the Ple155 promoter was incorporated into all further experiments.
Intravitreally injected AAV2(quadY-F+T-V)-Ple155 restores Nyctalopin expression to
Nyx nob ON BCs
Towards development of a clinically relevant approach, we examined the expression pattern of control eyes were identical to previous reports (13, 43, 48) . 
Gene replacement restores TRPM1 localization to dendritic tips of ON BCs and completely rescues ON BC TRPM1 channel gating
We previously showed that the expression of TRPM1 is lost in Nyx nob mice (24). Although the function of NYX is still incompletely understood, it is clearly required to localize TRPM1 to the Finally, the absence of LRIT3 also leads to an absence of TRPM1 in dendritic tips (27), but it is not known if this is a direct consequence or results from a change in NYX expression. There are several possible reasons why it is difficult to express NYX in P30-treated mice.
Optogenetic protein expression studies using intravitreal injection requires very high titer virus (38-41) to obtain widespread ON BC infection. Indeed, we observed that therapeutic effects were achieved when vector was delivered at 2.5 x 10 13 vg/mL but not at 3.8 x 10 12 vg/mL (data not shown). Thus, more viral particles may be required to make it through the barriers of the inner limiting membrane and plexiform layers to achieve sufficient transduction in the inner nuclear layer. However, the fact that AAV-mediated Nyx message was present in retinas injected at either P2 or P30 suggests that inefficient targeting of transgene to ON BCs is not the cause. Indeed, transcript levels were higher in P30-treated mice, a result likely attributed, in part, to the larger number of ON BCs available for transduction in the fully differentiated, P30 rodent retina (51, 52). Additionally, robust GFP expression mediated by AAV2(quadY-F+T-V)-transduced ON BCs at both time points, the Ple155 promoter was active, and that the hurdle to achieving efficient NYX expression/therapy in older mice may be post transcriptional.
Based on our results, it is clear that more work needs to be done to develop this strategy into a clinically translatable therapy. It is interesting to consider whether the window of therapy can be extended and if treatment, whether early or late, will resolve other phenotypes that accompany CSNB1. It is well known that the visual experience can impact synaptic function (54) . For example, dark rearing disrupts GRM6 localization in cone ON BC dendritic tips (55) . The absence of a functional ON pathway also affects eye development, leading to high myopia in CSNB1 patients (3) and increased susceptibility to form-deprivation myopia in mouse models with ON pathway defects (56, 57), a phenotype suggested to result from decreased dopamine metabolism/turnover within the retina (56, 57) . ON pathway defects also lead to reduced contrast sensitivity and cortical orientation selectivity (58) . Taken together, it is tempting to speculate that expression of ON BC proteins such as NYX are developmentally regulated at the translational or post-translational level.
In conclusion, this study shows for the first time that postnatal delivery of an ON BC specific PCR primers were designed to amplify selected regulatory regions (Table 2) . Briefly, human genomic DNA was amplified using PCP-X_OL_V1 and PCP2-X_OR_V1, generating a contiguous 4,500 bp PCR product containing all the regulatory regions of interest. To create the Ple155 MiniPromoter, two smaller regions were further amplified and a fusion PCR product generated as follows. Using the initial 4,500 bp PCR product, primers PCP2-ABD_P1R_MluI_V1 and PCP2-BD_P1L_V1 were used to amplify the Prom1 region. Primers PCP2-B_P2R_V1 and PCP2-B_P2L_SacI_V1 were used to generate the Prom2 region.
Subsequently, both Prom PCR products were used along with primers PCP2-ABD_P1R_MluI_V1 and PCP-2B_P2L_SacI_V1 to generate a fusion PCR product containing the entire MiniPromoter, which was subcloned using the MluI/SacI sites in the multiple cloning site of the pEMS1313 backbone vector (62) to yield the pEMS1626 plasmid (42) . Additional information and constructs are available from AddGene (www.addgene.org). injections, eyes were dilated with 1% Atropine, followed by 2.5% phenylephrine (both Akorn Inc, Lake Forest, IL). Mice were then anesthetized with ketamine (72 mg/kg)/xylazine(4 mg/kg) (Phoenix Pharmaceutical, St. Joseph, MO). Trans-corneal subretinal injections of virus (1µl)
Construction of AAV vectors:
were performed using a 33 gauge blunt needle on a Hamilton syringe. Trans-scleral intravitreal injections (1µl) were done using a 33 gauge beveled needle on a Hamilton syringe. P2 mice were anesthetized on ice and virus was delivered intraocularly (0.5l) using a 34 gauge beveled needle on a Hamilton syringe. Vectors were delivered undiluted in all cases.
Electroretinogram: After overnight dark adaptation, mice were anesthetized with a solution of ketamine (80 mg/kg) and xylazine (16 mg/kg). Eye drops were used to dilate the pupils (1% tropicamide and 2.5% phenylephrine HCl) and to anesthetize the corneal surface (1% proparacaine HCl). A pair of stainless steel wire electrodes were used to record ERGs from each corneal surface. These active leads were referenced to a needle electrode placed in the cheek. A second needle electrode placed in the tail served as the ground lead. ERGs were recorded using an LKC (Gaithersburg, MD) UTAS E-3000 signal averaging system. Responses evoked by ganzfeld strobe flash stimuli were band-pass filtered (0.03 -1,000 Hz), amplified, averaged, and stored.
The Nyx nob ERG is comprised primarily of response components generated by photoreceptors (a-wave), Müller glial cells (slow PIII), and hyperpolarizing bipolar cells (48), but is missing the positive polarity component generated by depolarizing bipolar cells (DBCs) (13). Because we were uncertain how AAV might impact the ERG waveform of treated mice, we repeated certain stimulus conditions multiple times for each mouse, to allow us to appreciate a consistent waveform change. With that exception, the recording protocol was comparable to that used for other mouse models. In each recording session, we began with dark-adapted responses to low luminance stimuli, and increased flash luminance as the session proceeded. Stimuli were presented in order of increasing luminance, and ranged in flash luminance from -3.6 to 2.1 log cd s/m 2 . After dark-adapted recordings were complete, cone ERGs were isolated by superimposing stimuli upon a steady adapting field (20 cd/m 2 ). Flash luminance ranged from -0.8 to 1.9 log cd s/m 2 . All Nyx nob mice intraocularly injected at P2 with AAV-Nyx (n=17) were analyzed by ERG. 
